CLINICAL_TRIALS
trial_result
· 2021-11-04
Clinical Trial Update: A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment [Phase 4]
Summary
A Phase 4 safety and efficacy trial of lesinurad 200 mg in participants with gout and renal impairment was terminated; results were posted in 2021.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ironwood Pharmaceuticals, Inc. | Conditions: Gout, Chronic Kidney Disease (CKD) | Phase 4 | Status: TERMINATED | Results posted: 2021-11-04